Cue BiopharmaCUE -3.36%59 PB Ratio is 3.79 as of Jun. 25, 2026, which is 2% above its 10-year median of 3.70. GuruFocus rates CUE with a GF Score™ of 59/100 and a GF Value™ of $62.11 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,233 Biotechnology companies, Cue Biopharma ranks worse than 62.61% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Cue Biopharma's share price is $25.135. Cue Biopharma's Book Value per Share for the quarter that ended in Mar. 2026 was $6.64. Hence, Cue Biopharma's PB Ratio of today is 3.79.
The historical rank and industry rank for Cue Biopharma's PB Ratio or its related term are showing as below:
CUE'
s PB Ratio Range Over the Past 10 Years
Min: 0.81 Med: 3.7 Max: 17.69
Current: 3.79
During the past 11 years, Cue Biopharma's highest PB Ratio was 17.69. The lowest was 0.81. And the median was 3.70.
CUE's PB Ratio is ranked worse than 62.61% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs CUE: 3.79
During the past 12 months, Cue Biopharma's average Book Value Per Share Growth Rate was 107.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -43.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -39.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -7.90% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Cue Biopharma was 69.60% per year. The lowest was -48.20% per year. And the median was -7.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cue Biopharma PB Ratio Related Terms
Cue Biopharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Cue Biopharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cue Biopharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cue Biopharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cue Biopharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cue Biopharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Cue Biopharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cue Biopharma (CUE) has a PB Ratio of 3.79 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cue Biopharma and its competitors. This is near median its historical median of 3.70. Over the past decade, Cue Biopharma's PB Ratio has ranged from 0.81 to 17.69. According to the industry distribution chart, Cue Biopharma ranks #772 out of 1233 companies in the Biotechnology industry, placing it in the top 62.6%.
Is Cue Biopharma's PB Ratio too high?
Cue Biopharma's current PB Ratio of 3.79 is near median its 10-year median of 3.70. Over the past 10 years, this metric has ranged from a low of 0.81 to a high of 17.69. The Biotechnology industry median PB Ratio is 2.80. Cue Biopharma's value of 3.79 is 35.4% above this industry median. Based on the distribution chart, Cue Biopharma ranks #772 out of 1233 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cue Biopharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's PB Ratio compare to TELO and ACET?
According to the Biotechnology industry distribution chart, Cue Biopharma ranks #772 out of 1233 companies for PB Ratio. This places Cue Biopharma in the lower half of its industry. The industry median PB Ratio is 2.80. Cue Biopharma's value of 3.79 is 35.4% above this benchmark. Historically, Cue Biopharma's own PB Ratio has ranged from 0.81 to 17.69 over the past decade. While the company's 10-year median is 3.70 vs. the industry median of 2.80, Cue Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cue Biopharma's current PB Ratio of 3.79 is 35.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cue Biopharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cue Biopharma's current PB Ratio is 3.79, which is near median its own 10-year median of 3.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (CUE) is currently considered Possible Value Trap. The stock's GF Value™ is $62.11, compared to a current price of $25.14 — trading 59.5% below its estimated fair value. The current PB Ratio is 3.79, which is near median its 10-year median of 3.70 and 35.4% above the Biotechnology industry median of 2.80. Cue Biopharma's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cue Biopharma (CUE), the current PB Ratio is 3.79 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cue Biopharma (CUE) Overvalued in 2026?
Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued.
The current stock price of $25.14 is trading 59.5% below its estimated GF Value™ of $62.11.
GuruFocus considers Cue Biopharma to be Possible Value Trap.
Key valuation signals for CUE:
PB Ratio: 3.79 (near median its 10-year median of 3.70)
GF Value™: $62.11 vs. price of $25.14 (59.5% below fair value)
Industry Position: 35.4% above the Biotechnology median (#772 of 1233)
No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
59GF Score
Get the complete analysis for CUE
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUE has been successfully added to your 
